Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 23, 2013

Illumina Acquires Microfluidics Firm Advanced Liquid Logic

  • Illumina has acquired digital microfluidics company Advanced Liquid Logic (ALL), the firm said today. Through the acquisition, ALL will become a wholly owned subsidiary of Illumina. Financial terms were not disclosed.

    The San Diego sequencing giant noted that ALL’s digital microfluidics technology is based on an electrowetting approach “that precisely manipulates small droplets within a sealed disposable cartridge to perform complex laboratory protocols.” The company added that ALL’s technology has been used for a variety of applications, from nucleic acid isolation to library generation for next-generation sequencing.

    Illumina said the addition of ALL’s technology to portfolio “will further streamline” its next-generation sequencing workflow customer offerings.

    “For clinical and applied markets, where ease of use and consistency are especially valued, it will allow us to offer integrated, end-to-end solutions,” Christian Henry, svp, general manager of Illumina's Genomic Solutions business, said in a statement. “ALL brings an impressive IP portfolio in digital microfluidics and a talented team with a track record of innovation.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »